- Home
- SPRO vs SRFM Comparison
SPRO vs SRFM Comparison
Compare SPRO & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- SRFM
- Stock Information
- Founded
- SPRO 2013
- SRFM 2011
- Country
- SPRO United States
- SRFM United States
- Employees
- SPRO N/A
- SRFM N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- SRFM Transportation Services
- Sector
- SPRO Health Care
- SRFM Consumer Discretionary
- Exchange
- SPRO Nasdaq
- SRFM Nasdaq
- Market Cap
- SPRO 63.0M
- SRFM 62.8M
- IPO Year
- SPRO 2017
- SRFM 2023
- Fundamental
- Price
- SPRO $0.97
- SRFM $3.88
- Analyst Decision
- SPRO Buy
- SRFM Hold
- Analyst Count
- SPRO 4
- SRFM 2
- Target Price
- SPRO $5.00
- SRFM $3.40
- AVG Volume (30 Days)
- SPRO 247.7K
- SRFM 732.8K
- Earning Date
- SPRO 11-14-2024
- SRFM 11-14-2024
- Dividend Yield
- SPRO N/A
- SRFM N/A
- EPS Growth
- SPRO N/A
- SRFM N/A
- EPS
- SPRO 0.06
- SRFM N/A
- Revenue
- SPRO $106,455,000.00
- SRFM $118,212,000.00
- Revenue This Year
- SPRO N/A
- SRFM $102.41
- Revenue Next Year
- SPRO N/A
- SRFM $47.46
- P/E Ratio
- SPRO $15.29
- SRFM N/A
- Revenue Growth
- SPRO 37.01
- SRFM 198.78
- 52 Week Low
- SPRO $0.92
- SRFM $0.90
- 52 Week High
- SPRO $1.89
- SRFM $10.08
- Technical
- Relative Strength Index (RSI)
- SPRO 39.40
- SRFM 45.78
- Support Level
- SPRO $0.92
- SRFM $5.13
- Resistance Level
- SPRO $1.13
- SRFM $6.59
- Average True Range (ATR)
- SPRO 0.06
- SRFM 0.91
- MACD
- SPRO 0.00
- SRFM -0.19
- Stochastic Oscillator
- SPRO 26.16
- SRFM 20.80
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.